Cytokine storm in COVID-19: the current evidence and treatment strategies

Y Tang, J Liu, D Zhang, Z Xu, J Ji, C Wen - Frontiers in immunology, 2020‏ - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is the pathogen that causes
coronavirus disease 2019 (COVID-19). As of 25 May 2020, the outbreak of COVID-19 has …

Immune-mediated inflammatory disease therapeutics: past, present and future

IB McInnes, EM Gravallese - Nature Reviews Immunology, 2021‏ - nature.com
Immune-mediated inflammatory diseases are common and clinically diverse. Although they
are currently incurable, the therapeutic armamentarium for immune-mediated inflammatory …

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

S Ramiro, E Nikiphorou, A Sepriano, A Ortolan… - Annals of the rheumatic …, 2023‏ - Elsevier
Objectives To update the Assessment of SpondyloArthritis international Society (ASAS)-
EULAR recommendations for the management of axial spondyloarthritis (axSpA). Methods …

ECCO guidelines on inflammatory bowel disease and malignancies

H Gordon, L Biancone, G Fiorino… - Journal of Crohn's …, 2023‏ - academic.oup.com
This guideline is the second European Crohn's and Colitis Organisation [ECCO] evidence-
based consensus on inflammatory bowel disease [IBD] and malignancy, and is an update …

EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis

G Nagy, NMT Roodenrijs, PMJ Welsing… - Annals of the rheumatic …, 2022‏ - Elsevier
Objective To develop evidence-based European Alliance of Associations for Rheumatology
(EULAR) points to consider (PtCs) for the management of difficult-to-treat rheumatoid …

COVID-19 infection and rheumatoid arthritis: Faraway, so close!

EG Favalli, F Ingegnoli, O De Lucia, G Cincinelli… - Autoimmunity …, 2020‏ - Elsevier
The outbreak of the new coronavirus infections COVID-19 in December 2019 in China has
quickly become a global health emergency. Given the lack of specific anti-viral therapies, the …

Role of inflammatory cytokines in COVID-19 patients: a review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to …

AA Rabaan, SH Al-Ahmed, J Muhammad, A Khan… - Vaccines, 2021‏ - mdpi.com
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), is a severe pandemic of the current century. The vicious …

Disease-modifying anti-asthmatic drugs

M Lommatzsch, GG Brusselle, GW Canonica… - The Lancet, 2022‏ - thelancet.com
Drugs available for asthma treatment in the first decades of the 20th century
(sympathomimetic agents such as oral ephedrine, intravenous adrenaline, or inhaled …

Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad

S Ahmed, O Zimba, AY Gasparyan - Clinical rheumatology, 2020‏ - Springer
The pathogenesis of Coronavirus disease 2019 (COVID-19) is gradually being
comprehended. A high number of thrombotic episodes are reported, along with the mortality …

[HTML][HTML] Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19

W Luo, YX Li, LJ Jiang, Q Chen, T Wang… - Trends in pharmacological …, 2020‏ - cell.com
Recent advances in the pathophysiologic understanding of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe …